BVS - CIK 0001665988
Bioventus Inc. trades as BVS. In its fiscal 2025 annual report the company posted revenue of $568.09M, down 0.9% from the prior year and net income of $22.73M. This page tracks Bioventus Inc. through 445 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Bioventus Inc.'s revenue grew from $340.14M to $568.09M, a compound annual growth rate of 8.9%. Net profit margin expanded from 2.0% to 4.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-14 |
| Insider trade | 4 | 2026-04-14 |
The largest companies sharing Bioventus Inc.'s SEC industry classification (surgical & medical instruments & apparatus).
Bioventus Inc. reported revenue of $568.09M for fiscal year 2025, a decrease of 0.9% year over year.
Yes. Bioventus Inc. reported net income of $22.73M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.